secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-267934
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular announces positive interim 1.5-3.5 year data for 4D-150 in wet AMD; 79-92% injection reduction
--------------------------------------------------------------------------------

- Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.
- Phase 2b recently diagnosed subgroup (Phase 3 comparable): 92% reduction in mean supplemental injections vs aflibercept at 1.5 years.
- Phase 2b broad cohort: 82% reduction; Phase 1/2a severe recalcitrant: 79% reduction at 2 years.
- Safety: 2.8% (2/71) mild transient IOI within 28 weeks; no new IOI after 28 weeks; no hypotony, endophthalmitis, vasculitis.
- Consistent dose response favoring Phase 3 dose (3E10 vg/eye) over lower dose across all cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525267934/0001193125-25-267934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525267934/d280681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-267934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer